Acetaminophen toxicity: Changing perceptions on a social/medical issue
William M. Lee – 25 September 2007
Different fat distribution as marker of disease in nonalcholic fatty liver disease
Melania Manco, Valerio Nobili – 25 September 2007
Reply:
Onpan Cheung, Arun J. Sanyal – 25 September 2007
Re‐evaluating the use of growth factors as adjuvant treatment of chronic hepatitis C
- Read more about Re‐evaluating the use of growth factors as adjuvant treatment of chronic hepatitis C
Howard J. Worman – 25 September 2007
Geotherapeutics of primary biliary cirrhosis: Bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom
Christophe Corpechot, Raoul Poupon – 25 September 2007
Reply:
Jonel Trebicka, Tilman Sauerbruch, Jörg Heller – 25 September 2007
Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial
Ira M. Jacobson, Robert S. Brown, Bradley Freilich, Nezam Afdhal, Paul Y. Kwo, John Santoro, Scott Becker, Adil E. Wakil, David Pound, Eliot Godofsky, Robert Strauss, David Bernstein, Steven Flamm, Mary Pat Pauly, Pabak Mukhopadhyay, Louis H. Griffel, Clifford A. Brass – 25 September 2007 – This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG‐IFN) alfa‐2b plus a flat or weight‐based dose of ribavirin (RBV) in adults with chronic hepatitis C.
Is interleukin‐6 a gender‐specific risk factor for liver cancer?
Leif E. Sander, Christian Trautwein, Christian Liedtke – 25 September 2007
Bioinformatics as tool to identify gene/protein‐pathways associated with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Anna Alisi, Matilde Marcellini, Valerio Nobili – 25 September 2007
Atorvastatin and portal pressure
Daniel Zamora‐Valdés, Misael Uribe, Nahum Méndez‐Sánchez – 25 September 2007